Though high rates of the disease persist among the nearby Indigenous communities, the Canadian government is weighing rules that may allow energy giants to release treated mining waste into the river ...
He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...
Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva has the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results